

I. BIOGRAPHICAL DATA

Dr. Jodie M. Burton

Office:
Health Sciences Centre, room 1007c
3330 Hospital Drive NW
Calgary, AN
T2N 4N1
Tel: 403 210-6614

Home:
2302-650 10th St SW
Calgary, AB
T2P 5G4
Tel: 403 441-5573

Assistant Clinical Professor
Department of Clinical Neurosciences and Department of Community Health Sciences
Faculty of Medicine
University of Calgary

II. ACADEMIC RECORD

i. Undergraduate:

HonBSc
1996
Life Sciences
University of Toronto/Toronto/Canada

ii. Graduate and Postdoctoral:

Doctor of Medicine (MD)
2000
University of Toronto/Toronto/Canada

Medical Residency (Neurology)
2005
University of Toronto/Toronto/Canada

Fellowship
2005-2007
Multiple Sclerosis
University of Toronto/Toronto/Canada

Masters of Science (MSc)
2008
Clinical Epidemiology
University of Toronto/Toronto/Canada

iii. Licensure, Certification and Boards (e.g. FRCPC):

Independent License/Full Member, College of Physicians and Surgeons of
Alberta
2009

Fellow/Full Member, Royal College of Physicians and Surgeons of Canada
2007

Independent License/Full Member, College of Physicians and Surgeons of
Ontario
2005

Licentiate, Medical Council of Canada
2001

III. **AWARDS AND DISTINCTIONS**

2014-2015 Neurology AARP Merit Award, Division of Neurology, Alberta
Health Services

2013-2014 Distinguished Reviewer of the Year, Canadian Journal of
Neurological Sciences

2013-2014 endMS Graduate Student Support Grant for MSc candidate R.
Klein for study "The Influence of Menstrual History on MS" (\$13,500)

2012 Blue Ribbon Poster Prize for "The Role of Vitamin D Status in Optic
Neuritis Recovery", The North-American Neuro-Ophthalmology Society
Annual Meeting, North American Neuro-Ophthalmology Society

2012-2013 endMS Graduate Student Support Grant for MSc candidate J.
Trufyn for study "The Role of Reproductive Hormones and Oral
Contraception in Optic Neuritis ("ROC-ON") (\$13,500)

2010 Charcot Young Investigator of 2010 Award, European Charcot Foundation (€5,000)

2006-2007 John Wherret Fellowship Presentation Award, University of Toronto

1999-2001 Walter F. Watkins Scholarship, Doctor of Medicine Program, University of Toronto

1996 Armando and Nicola Pavone Outstanding Achievement, Faculty of Medicine, University of Toronto

1996 Burton Scholarship (no relation), University of Toronto

1993-1996 Dr. J.A. and Connie Dickson Scholarship, University of Toronto

1992-1996 Canada Scholar, Government of Canada

1992-1996 Arthur Cohen Scholarship, University of Toronto

1995 David Ketchum Memorial Scholarship, University of Toronto

1993 Ann Shepard Memorial Scholarship in Biology, University of Toronto

1992 Ontario Scholar, Ontario Ministry of Education

IV. ACADEMIC APPOINTMENTS

2010 Assistant Clinical Professor, Community Health Sciences, University of Calgary

2010 Full Member, Hotchkiss Brain Institute, University of Calgary

2009 Assistant Clinical Professor, Clinical Neurosciences, University of Calgary

2007-2009 Lecturer/Staff Neurologist, Division of Neurology, University of Toronto

V. EDUCATIONAL ACTIVITIES

i. Undergraduate

2009, 2016-2017 Small group lead, Course V (Neurosciences) Cumming School of Medicine, University of Calgary (total 12 hours)

2013 Reviewer/Panel Member, Health Science Inquiry Competition/Annals of Internal Medicine Review Panel. Member of review panel for student competition for papers on Mental Health and Neurological Disorders. Submissions are reviewed for possible publication in Annals of Internal Medicine

2012-2013 Principal Supervisor University of Calgary HonBSc student Rebecca Klein "Honours Thesis and Research Communication" course, Bachelors of Science Program, University of Calgary. Her project (May 2012-May 2013) revolved around our study "The Role of Oral Contraceptives and Sex Hormones in Optic Neuritis (ROC-ON)".

2010-2012 Lecturer, Course V (Neurosciences) Annual Lecture on Multiple Sclerosis, Cumming School of Medicine, University of Calgary (total 4 hours).

2011 Principal Supervisor University of Calgary BSc student Chelsia Tung for project "The Role of Vitamin D in Optic Neuritis Recovery". Her project was supported by an endMS/MS Society of Canada Summer Studentship Award.

ii. Graduate (course and student supervision)

MSc:

2018-2020 MSc Thesis Committee Member for Natalie Tsao, University of Calgary (Supervisor Dr. Douglas Syme)

2017-2019 MSc Thesis Committee Member for Shahnewaz Hossain, Medical Sciences Graduate Program, University of Calgary (Supervisor Dr. Yuyan Zhang)

2013-2014 MSc Supervisor for Rebecca Klein, Neurosciences Graduate Program, University of Calgary for project "The Influence of Menstrual History on Multiple Sclerosis" (not completed).

2011-2013 MSc Co-Supervisor for Jessie Trufyn, Neurosciences Graduate Program, University of Calgary for project "The Role of Female Hormones in Optic Neuritis" (completed).

2005-2007 MSc Co-Supervisor for Samantha Kimball, Nutritional Sciences, University of Toronto for thesis "The Therapeutic Potential of Vitamin D3 in Multiple Sclerosis" (completed).

PhD:

2010-2014 PhD Academic Advisor/Member of Supervisory Committee for Sandra Berzins, Department of Community Health Sciences, University of Calgary for thesis "Determinants of Mental Health and Well-being in MS" (completed).

2011, PhD Academic Advisor for Constantina Lafoyiannis, Department of Psychology, York University/Hospital for Sick Children for thesis "Optical Coherence Tomography as a Window to the Mind: Axonal Integrity and Cognitive Performance in Youth with Pediatric Multiple Sclerosis" (completed).

2007-2010 PhD Co-Supervisor for Kimball Samantha, Nutritional Sciences, University of Toronto for thesis "The Therapeutic Potential of Vitamin D3 in Multiple Sclerosis" (completed)

Other/Residents:

2018, 2017, 2015 Royal College MS Preparation Sessions for University of Calgary Neurology/Pediatric Neurology candidates

2009-present Co-Instructor, Resident Evidence Based Medicine Curriculum Division of Neurology, University of Calgary (10 hours/y including prep)

2010, 2015 OSCE Examiner, Senior Neurology resident OSCE examiner, University of Calgary

2011 OSCE Developer and Examiner, LAUNCH National Resident OSCE Program, LAUNCH Canadian Resident Program

iii. Postgraduate (research and clinical fellows)

2015-present Supervisor to Neurology resident Daniel Fok, Division of Neurology, University of Calgary for Quality Improvement project "Resident Perception of Current Handoff Practices and Future Directions"

2011-present Co-Supervisor to Neurology resident members of the M&M/Quality Assurance Committee, Division of Neurology, University of Calgary

2013 Advisor for design and biostatistical support for resident Andrew Won H Ryu, Division of Neurosurgery, University of Calgary for his work on "PITNET (a registry and study of visual outcomes in patients with pituitary adenomas)

2013 Member, Judging Panel for graduate students submissions (5), to volume 4 of Health Science Inquiry, a publication that in May 2013 was focused on graduate student papers on Neurology and Mental Health (published through the University of Toronto).

iv. Continuing Medical Education

2016 Co-director, Western MS Literature Review, Calgary, AB

2016, 2015, Invited speaker, "Practical Issues in Switching and Escalating MS Therapeutics", MS Clinic Providers in Calgary AB, Edmonton, AB, and Saskatoon, SK

2015, Invited speaker, "Practical Issues in Switching and Escalating MS Therapeutics", MS Clinic Providers, Edmonton, AB

2011 MS Update, Friday Afternoon at the Medical School, University of Calgary

2010 Emerging Therapies in MS, 27th Ann. Calgary Therapeutics Course, University of Calgary

VI. ADMINISTRATIVE RESPONSIBILITIES

i. Departmental

2016-present Director, MS Clinic Rounds, Division of Neurology, University of Calgary

2011-present Co-Lead Administrator, Quality Assurance and Morbidity and Mortality Committee, Division of Neurology, Department of Clinical Neurosciences, University of Calgary

2010-present Inpatient Demyelinating Consult Service, Division of Neurology, University of Calgary

2010-present Urgent Neurology Clinic Triage, Division of Neurology, University of Calgary

2013-2016 Central Access General Neurology Triage, Division of Neurology, University of Calgary

ii. University

2014-present Co-Director, Autologous Hematopoietic Stem Cell Transplant Program for Multiple Sclerosis, University of Calgary

iii. Regional Health Authority

2016-present Clinical Topic Lead - Neuromyelitis Optica Clinical Knowledge and Content Management – Clinical Information Systems, Alberta Health Services

2014-present Co-author (with Dr. J. Storek) of guidelines for AHST in MS, BMT Standard Practice Manual, Alberta Health Services,

<http://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-bmt-manual.pdf>

2010 Development of Protocol, Guidelines and Management of the use of Cyclophosphamide in Demyelinating/MS Patients, in use across Calgary Zone and made available nationwide upon request

iv. Hospital

2010-present Specialist Consultant for cyclophosphamide use/aggressive inpatient demyelinating cases

VII. PROFESSIONAL ACTIVITIES

i. Membership in Professional and Learned Societies:

2017-2019 Vice President, Canadian Neurological Society

2015-2017 Secretary-Treasurer, Canadian Neurological Society

2015-present Member, Fellowship Committee, Canadian Network of MS Clinics

2009-present Hotchkiss Brain Institute, University of Calgary

2009-present College of Physicians and Surgeons of Alberta

2009-present Alberta Medical Association

2005-present Fellow, College of Physicians and Surgeons of Ontario

2000-present Ontario Medical Association

ii. Professional Service

Grant panels:

2010-2012, Member, Multiple Sclerosis Society of Canada Biomedical Grant Review Committee

Grant Review Services:

2015, External reviewer, Neurological Foundation of New Zealand

2014, External reviewer, Health Research Ethics Board of Alberta (HREBA)

2014, External reviewer, Irish Institute of Clinical Neuroscience

2013 Member, for Calgary Surgical Research Development Fund Review Committee. Reviewed research applications from residents within the Department of Surgery, University of Calgary.

2009, 2010, External reviewer, MS Society of Canada

Journal Reviews:

2012-present: Canadian Journal of Neurological Sciences JNS (~25), Multiple Sclerosis (13), Multiple Sclerosis and Related Diseases (18), JNNP (2), CMAJ (2), Lancet, Acta Neurological Scandinavica, Neuroscience, International Journal of Molecular Sciences

2013 Reviewer/Panel Member, Health Science Inquiry Competition/Annals of Internal Medicine Review Panel. Student competition for papers on Mental Health and Neurological Disorders. Submissions were reviewed for possible publication in Annals of Internal Medicine.

Conference Abstract Reviews:

2017 Abstract reviewer for annual American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) meeting

2016-present Abstract reviewer for annual Canadian Neurological Society Federation Congress Meeting

Editorships:

2012-present, Editorial Board member, Canadian Journal of Neurological Sciences

National and International Committees:

2016-present Member, International Multiple Sclerosis Visual System Consortium (IMSVISUAL). An international working group for the improvement of research and education in multiple sclerosis (MS) and other neuroinflammatory disorders by advancing our understanding of the visual system in MS.

2015-present Member, Guthy Jackson Charitable Foundation for NMO Research.

2012-present Member, Vitamin D3 and Multiple Sclerosis Prevention International Working Group. A group of international experts in MS, clinical research, vitamin D biochemistry and epidemiology working towards the implementation of an international MS prevention using vitamin D and the generation of guidelines/position papers

2012-present Member, International Autologous Hematopoietic Cell Transplant in Multiple Sclerosis Trial Working Group: Meetings in Montreal, Quebec (July 2011) and Amsterdam, The Netherlands (Oct 2011) and Lyon (October 2012) of an international group of neurologists, transplant specialists and other researchers to plan an international multicentre trial of stem cell transplantation in multiple sclerosis

Conference Chair Duties:

2018 Chair, Neuroimmunology CNS Half Day, Canadian Neurological Society Federation Congress Meeting, Halifax, NS

2017 Co-chair, Keynote Session “Do Remyelination Therapies Provide Axonal Protection after Inflammatory Demyelination?”, Alberta MS Network Retreat, Dec 2017, Banff, AB

2017 Co-chair, Session “The Diet and Multiple Sclerosis”, ACTRIMS 2017, Orlando, FL.

2014, 2015 Co-chair, Multiple Sclerosis Half Day, Canadian Neurological Society Federation Congress Meeting (Banff, AB and Toronto, ON respectively)

Community/Volunteer Activities:

2013-2014 Consultant, EMD Serono/MS Village. Online forum through “MS Village” website for patient education in MS for which I would provide expert answers to patient queries monthly.

VIII. RESEARCH SUPPORT (active projects have title in bold)

Investigating if autophagy is involved in the switch from relapsing-remitting multiple sclerosis to progressive multiple sclerosis

Principal Investigator: Shalina Ousman

Co-investigator: JM Burton

Funding Source: Pilot Research Fund Program (PFUN), Hotchkiss Brain Institute, University of Calgary

Application under review for 2018-2020

Amount To Be Awarded: \$20,000 CAN

Funding Competitive?: Yes

A Phase II Trial of Vitamin D Induction in Optic Neuritis (VitaDON Treatment Trial)

Principal Investigator: JM Burton

Co-Principal Investigator: Fiona Costello

Co-investigators: Bruce Pike; Gordon Fick; Nils Forkert; Yunyan Zhang;

Collaborators: Alexander Klistorner; Alex Brandt; Samantha Kimball

Funding Source: Multiple Sclerosis Translational Research Fund, Hotchkiss Brain Institute, University of Calgary

Funding Period: 2017/4 - 2021/4

Amount Awarded: \$350,000 CAN

Funding Competitive?: Yes

Evaluating the neuroprotective effects of Vitamin D Induction in Optic Neuritis

Principal Investigator: Fiona Costello

Co-Principal Investigator: JM Burton

Funding Source: Lions Sight Centre Fund

Funding Period: 2015/11-2017/11

Amount Awarded: \$19,000 CAN

Funding Competitive?: Yes

Studying the Immunological Profile of Neuromyelitis Optica (NMO) Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Principal Investigator: JM Burton

Co-applicant: Jan Storek

Co-investigator: May Han

Funding Source: Pilot Research Fund Program (PFUN), Hotchkiss Brain Institute, University of Calgary

Funding Period: 2015/5-2016/5

Amount Awarded: \$20,000 CAN

Funding Competitive?: Yes

The Influence of Menstrual History on Multiple Sclerosis

Principal Investigator: JM Burton

Funding Sources: Alberta endMS (MS Society of Canada)

Funding Period: 2013/9 - 2014/8

Amount Awarded: \$13,500 CAN

Funding Competitive?: Yes

The Influence of Hormonal Contraception Use and Reproductive Hormone Levels in Women with Optic Neuritis

Principal Investigator: JM Burton

Co-Principal Investigator: Fiona Costello

Collaborator: Gordon Fick

Funding Sources: University of Calgary Seed Grant

Funding Period: 2012/8 - 2013/8

Amount Awarded: \$16,091 CAN

Funding Competitive?: Yes

The Role of Reproductive Hormones and Oral Contraception in Optic Neuritis (ROC-ON)

Principal Investigator: JM Burton

Co-Principal Investigator: Fiona Costello

Funding Sources: Alberta endMS (MS Society of Canada)

Funding Period: 2012/9 - 2013/8

Amount Awarded: \$13,500 CAN

Funding Competitive?: Yes

Hematopoietic Stem Cell Transplant in Patients with Neuromyelitis Optica

Principal Investigator: JM Burton

Co-investigators: Jan Storek, Peter Duggan, Fiona Costello, Luanne Metz

Funding Source: Internal support, MS Research Program, Foothills Medical Centre, University of Calgary

Trial Period: 2010-2015

This was a single center trial of non-ablative autologous hematopoietic stem cell transplant in patients with Neuromyelitis Optic (NMO) who have failed standard therapy. Three eligible NMO patients were treated with a non-ablative autologous hematopoietic stem cell transplant and followed for 5 years with a primary outcome of relapse-free status at year three, and secondary outcomes including overall survival, relapse rate, disability, and retinal nerve fiber layer integrity. The trial closed in 2015 due to recruitment challenges.

A Phase I/II Dose-Escalation Trial of Vitamin D3 and Calcium in Multiple Sclerosis

Principal Investigator: JM Burton

Co-investigators: Amit Bar-Or, Hans-Michael Dosch, Dr. Paul O'Connor, Reinhold Vieth, Samantha Kimball

Funding Sources: Diet Research into the Cause and Treatment of Multiple Sclerosis (DIRECT-MS)

Funding Period: 2006/5 - 2009/6

Amount Awarded: \$200,000 CAN

Funding Competitive?: Yes

Defining markers of neuro-axonal injury and repair in a compressive model of optic neuropathy

Principal Investigator: Fiona Costello

Co-applicant: Yves Starreveld

Co-investigators: JM Burton, Alam Mitha, Andrew Ryu, Brad Goodyear, Stefan Lang

Funding Source: Pilot Research Fund Program (PFUN), Hotchkiss Brain Institute, University of Calgary

Funding Period: 2016/5-2018/5

Amount Awarded: \$20,000 CAN

Funding Competitive?: Yes

The NEurological diseasE and Depression Study (NEEDS) – addressing the burden, course and impact of depressive disorders in neurological conditions

Principal Investigator: Nathalie Jette

Co-Principal Investigator: Scott Patten

Co-investigators: JM Burton, AG Bulloch, S Wiebe, and other members of the NEEDS study group

Funding Sources: Alberta Health Services, University of Calgary Faculty of Medicine Team Grant Program, Hotchkiss Brain Institute

Funding Period: 2011-2015

Amount Awarded: \$480,000

Funding Competitive?: Yes

Knowledge Synthesis Grant: Systematic reviews of the evidence that tests for chronic cerebrospinal venous insufficiency (CCSVI) are valid and reproducible, that CCSVI is associated with MS and of the benefits and harms of endovascular therapy for MS

Principal Investigator: Andreas Laupacis

Co-investigators: **JM Burton**, Andrew Dueck; Julian Spears; Kevin Thorpe; Laure Perrier, Richard Aviv, Sharon Straus, Thomas Feasby, Erin Lillie

Funding Sources: Canadian Institutes of Health Research (CIHR) Knowledge Synthesis Grant: Evidence On Tap

Funding Period: 2011/1-2012/3

Amount Awarded: \$99,000 CAN

Funding Competitive?: Yes

IX. INVITED ADDRESSES

2016 Invited speaker, "Symptom Management in Multiple Sclerosis", Sam Darwish Memorial Lecture, Alberta Children's Hospital, University of Calgary, Calgary, AB

2016 Invited speaker, "Management of Aggressive CNS Demyelinating Disease", Grand Rounds, Critical Care Medicine, University of Calgary, Calgary, AB

2016 Invited speaker, "Treatment Strategies in Neuromyelitis Optica Spectrum Disorder (NMOSD) – A Canadian Perspective). Canadian Neurological Sciences Federation Annual Meeting, 2016, Quebec City, QC

2014 Invited speaker, Whitaker Research Track (Platform) Competition, "The Role of Vitamin D and Gender in Optic Neuritis". ACTRIMS/CMSC meeting, Dallas, TX.

2014, Invited speaker, "Practical Issues in Switching and Escalating MS Therapeutics", Canadian Neurological Sciences Federation Annual Meeting, 2014, Banff, AB

2014, Invited speaker, "What's New and Old in MS Therapeutic", Internal Medicine Grand Rounds, University of Calgary, Calgary, AB

2013 Platform presentation of "The Role of Vitamin D in Optic Neuritis Update - Platform Presentation and Highlights Section" Presented at 65th Ann. American Academy of Neurology meeting, San Diego, CA

2012 Invited speaker, "The Role of Vitamin D in Demyelinating Disease", Grand Rounds, Division of Neurology, General Hospital, Ottawa, ON

2010 Telus World of Science (Calgary) Body Worlds and the Brain, "Multiple Sclerosis in Alberta"

2010 Critical Appraisal of Literature in Multiple Sclerosis, Western MS Nurses Review Program Presentation, Calgary, AB

2009 Platform presentation of “Vitamin D3 in Multiple Sclerosis”, Ann. Meeting of Consortium of MS Clinics, Atlanta, GA

2008 Invited speaker, “Role of Vitamin D in Multiple Sclerosis, Division of Neurology, University of Calgary

2008 Invited speaker, “Vitamin D and Multiple Sclerosis”, Division of Neurology, Queen’s University, Kingston, Ontario

2008 Platform presentation of “A Phase I/II Dose Escalation Trial of Oral Vitamin D3 with Calcium Supplementation in Patients with Multiple Sclerosis”. Presented at 60th Ann. American Academy of Neurology meeting, Chicago, IL

2004 Platform presentation of “Neurological Manifestations of West Nile Virus Infection”. Presented at the 56th Ann. American Academy of Neurology meeting, San Francisco, CA

X. PUBLICATIONS/PRESENTATIONS (trainees underlined)

i. Peer Reviewed Manuscripts (published)

1. Pham T, Jetté N, Bulloch AGM, **Burton JM**, Wiebe S, Patten SB. The prevalence of anxiety and associated factors in persons with multiple sclerosis. *Mult Scler Relat Disord* 2017;19: 35-39.
2. Berzins SA, Bulloch AG, **Burton JM**, Dobson KS, Fick, GH, Patten SB. Determinants and incidence of depression in multiple sclerosis: A prospective cohort study. *J Psychosom Res* 2017;99: 169-176.
3. **Burton JM**. Oral rather than intravenous corticosteroids should be used to treat MS relapses – Commentary. *Mult Scler* 2017;23(8): 1060-1062. doi: 10.1177/1352458517697831. Epub 2017 Feb 1.
4. Baxter LJ, Chen S, Couillard P, Scott JN, Doig CJ, Costello F, Girard LP, Klassen J, **Burton JM**. Refractory longitudinally extensive transverse myelitis responsive to cyclophosphamide. *Can J Neurol Sci* 2017;Jul 20:1-4. doi: 10.1017/cjn.2017.201
5. Ryu A, Costello F, **Burton JM**, Starrveld Y. The utility of MRI in assessing patients with pituitary macroadenomas with compression of the afferent visual pathway. *J Neuroophthalmol* 2016 Jul 7. [Epub ahead of print]
6. **Burton JM**, Eliasziw M, Trufyn J, Tung C, Carter G, Costello F. A prospective Cohort study of vitamin D in optic neuritis recovery. *Mult Scler* 2016;23(1): 82-93.
7. **Burton JM**, Costello F. Vitamin D in multiple sclerosis and CNS demyelinating disease – a review. *J Neuroophthalmol* 2015;35(2): 194-200.
8. Zhornitsky S, Greenfield J, Koch M, Patten SB, Harris C, Wall W, Alikhani K, **Burton J**, et al. Long-Term persistence with injectable therapy in relapsing-remitting multiple sclerosis: An 18-year observational cohort study. *PLOS One* 2015;10(4): e0123824.

9. Costello F, Yeh A, **Burton JM**, Hodge W, Pan I, Kardon R. The temporal evolution of structural and functional measures after acute optic neuritis. *J Neurol Neurosurg Psychiatry* 2015;86(12): 1369-73.
10. Patten SB, **Burton JM**, Fiest KM, Wiebe S, Bulloch AGM, Koch M, et al. The validity of four screening scales for major depression in MS. *Mult Scler* 21(8): 1064-1071.
11. Costello F, **Burton JM**, AG Lee. Neuro-Ophthalmologic manifestations of multiple sclerosis. 2015 Medscape. <https://emedicine.medscape.com/article/1214270>
12. Kimball S, Hanwell HE, **Burton JM**, Heaney RP, et al. Vitamin D supplementation in multiple sclerosis: Making a case for clarity. *J Neurol Sci* 2014;347.
13. **Burton JM**, Costello F. Does this optic neuritis patient have neuromyelitis optica? An approach to optic neuritis in the context of neuromyelitis optica. *Expert Rev Ophthalmol* June 2014;9(3): 205-216 (doi: 10.1586/17469899.2014.922874).
14. **Burton JM**, Costello F. A review of the anterior visual pathway model and the study of vitamin D in demyelinating disease. *Mult Scler Relat Disord* 2014;3(1): 22-27.
15. Trufyn J, Hill MD, Scott JN, Modi J, Ciura V, Frayne R, Goyal M, Lautner D, Bhayana D, Davenport WJ, Mah JK, **Burton JM**, Costello F. The prevalence of incidental findings in multiple sclerosis patients. *Can J Neurol Sci* 2014;41(1): 49-52.
16. Costello F, **Burton JM**. An approach to optic neuritis: The initial presentation. *Expert Rev Ophthalmol* 2013;6(8): 539-551.
17. Costello F, Hodge W, Pan YI, **Burton JM**, Freedman MS, Stys P, et al. Sex-specific differences in retinal nerve fiber layer thinning after acute optic neuritis. *Neurology* 2012;79(18):1866-1872.
18. **Burton JM**, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. *Cochrane Database Syst Rev* 2012 Dec 12;12:CD006921.
19. **Burton JM**, Alikhani K, Goyal M, Costello F, White C, Patry D, Bell R, Hill MD. Complications in MS patients after CCSVI procedures abroad (Calgary, AB). *Can J Neurol Sci* 2011;38(5):741-746.
20. Kimball S, Vieth R, Dosch HM, Bar-Or A, Cheung R, Gagne D, O'Connor P, D'Souza C, Ursell M, **Burton JM**. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. *J Clin Endocrinol Metab* 2011;96(9):2826-2834.
21. Laupacis A, Lillie E, Dueck A, Straus S, Perrier L, **Burton JM**, et al. Association between chronic cerebrospinal venous insufficiency and multiple sclerosis: a meta-analysis. *CMAJ* 2011;183(16):E1203-1212.
22. Kimball SM, **Burton JM**, O'Connor PG, Vieth R. Urinary calcium response to high dose vitamin D3 with calcium supplementation in patients with multiple sclerosis. *Clin Biochem*. 2011;44(10-11): 930-932.
23. **Burton JM**, Costello F. Novel agents and emerging treatment strategies in multiple sclerosis. *Clin Med Rev in Therapeutics* 2011; 3: 235-257.
24. **Burton JM**, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. *Neurology* 2010; 74(23):1852-1859.

25. **Burton JM**, Bell CM, Walker SE, O'Connor P. A case series of 4-aminopyridine toxicity with unintentional overdose in patients with multiple sclerosis). *Neurology* 2008; 71(22): 1833-1834.
 26. **Burton JM**, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. *Cochrane Database of Systematic Reviews* 2009, Issue 3. Art. No.: CD006921. DOI: 10.1002/14651858.CD006921.pub2.
 27. **Burton JM**, Kern RZ, Halliday W, Mikulis D, Brunton J, Pepperell C, Jaigobin C. Neurological manifestations of West Nile Virus infection. *Can J Neurol Sci* 2004;31:185-193.
 28. Pepperell, C, Rau N, Krajden S, Kern R, Humar A, Mederski B, Simor A, Low DE, McGeer A, Mazzuli T, **Burton J**, Jaigobin C, Fearon M, Artsob H, Drebot MA, Halliday W, Brunton J. West Nile virus infection in 2002: Morbidity and mortality among patients admitted to hospital in south-central Ontario. *CMAJ* 2003;168: 1399-1414.
- ii. Peer Reviewed Manuscripts (submitted)
1. Burton JM, Traboulee T. Nothing Ventured, Nothing Gained? Navigating the Evolving Disease Modifying Treatment Landscape in Multiple Sclerosis (Editorial). *Can J Neurol Sci*, 2018, submitted for publication
 2. Costello F, **Burton JM**. Retinal imaging with optical coherence tomography: A biomarker in multiple sclerosis? *J Neuroophthalmol* 2018, invited review submitted for publication
 3. Chung H, Burton JM, Costello F. Transient vision loss. *Expert Rev Ophthalmol*, 2018, invited review submitted for publication
 4. Costello F, **Burton JM**. The 2018 Journal of Neuro-Ophthalmology Disease of the Year: Multiple Sclerosis: Eyes on the Future (Editorial). *J Neuroophthalmol* 2018, in press.
- iii. Non-peer Reviewed Manuscripts
1. **Burton JM**. The Role of Vitamin D in Multiple Sclerosis. *MS in Focus*, Multiple Sclerosis International Foundation (Issue 15, January 2010).
 2. Gladstone DJ, Zinman L, **Burton J**, Casaubon L, Chan D, Cashman N, Black SE, Freedman M. Recognition of the non-Alzheimer's Dementias: Highlights from the University of Toronto Behavioural Neurology Clinic Day. *Geriatrics and Aging* 2004;7: 53-59.
- iv. Books, Chapter
1. Fiona Costello, **Jodie M. Burton**. Chapter 3 - When Should You Consider the Diagnosis of Neuromyelitis Optica? *Curbside Consultation in Neuro-ophthalmology*, 2nd edition. Published, Slack Inc.
 2. **Burton, Jodie M**, O'Connor, Paul. Multiple sclerosis clinical trial design and analysis. *CONTINUUM: Lifelong Learning in Neurology* December 2004;Volume 10(6): 73-196.

3. Silver R, **Burton JM**, Parikh A. (Eds). Endocrinology. MCCQE 2000 Review Notes and Lecture Series, 16th ed. Law M and Rotenberg BW, Editors-in-chief. Toronto: MCCQE 2000.
- v. Abstracts - published
 1. Bhan V, Lapierre Y, Devonshire V, Emond F, Morrow SA, **Burton JM**, et al. Fingolimod in routine clinical practice: Canadian experience. *Mult Scler* 2016; P640.
 2. Baxter L, Chen S, **Burton J**. P.049 Medically refractory longitudinally extensive transverse myelitis successfully treated with cyclophosphamide induction. *Can J Neurol Sci* 2016;43(S2): S32-S33.
 3. Ryu WHA, Chan W, **Burton JM**, et al. Structural analyses of the anterior visual pathway in compressive neuropathy". North American Neuro-Ophthalmology Society (NANOS), 41st Annual Meeting. *J Neuroophthalmol* 2015;35(2): e28
 4. **Burton JM**, Storek P, Duggan P, et al. Autologous Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica – Four Year Update. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2015;21(S11): P245.
 5. **Burton JM**, Storek P, Duggan P, et al. Autologous Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica – An Update. Annual Meeting of the American Academy of Neurology. *Neurology* 2015;84 (Meeting Abstracts): P5.259.
 6. **Burton JM**, Storek P, Duggan P, et al. Autologous Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica – An Update. Annual Meeting of the American Academy of Neurology. *Neurology* 2014;82 (Meeting Abstracts): P4.001.
 7. Klein R, **Burton JM**. The Gender Divide in Multiple Sclerosis: A Review of the Environmental Factors Influencing the Increasing Prevalence of Multiple Sclerosis in Women. Annual Meeting of the American Academy of Neurology. *Neurology* 2014;82 (Meeting Abstracts): P4.024.
 8. **Burton JM**, Trufyn J, Tung C, et al. The Role of Vitamin D in Optic Neuritis—an Update. Annual Meeting of the American Academy of Neurology. *Neurology* 2014;82 (Meeting Abstracts): P6.147
 9. **Burton JM**, Storek P, Duggan P, et al. Autologous Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2014;20 (Issue 1, Supp): P898.

10. **Burton JM**, Trufyn J, Tung C, et al. The Role of Vitamin D and Gender in Optic Neuritis Recovery. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2014; 20 (Issue 1, Supp): P716.
11. **Burton JM**, Storek P, Duggan P, et al. An Update on Autologous hematopoietic stem cell transplant in patients with neuromyelitis optica. Annual Meeting of the American Academy of Neurology. *Neurology* 2013;80: 7 Supplement P02:151
12. Costello F, **Burton JM**, Trufyn J, et al. Exploring The Evolution Of Structural and Functional Changes After Optic Neuritis. Fifth Cooperative Meeting of CMSC and ACTRIMS. *International Journal of MS Care* 2013, Vol. 15, No 5.2.
13. **Burton JM**, Trufyn J, Tung C, et al. The Role of Vitamin D and Gender in Optic Neuritis Recovery. Fifth Cooperative Meeting of CMSC and ACTRIMS. *International Journal of MS Care* 2013, Vol. 15, No P.2.
14. **Burton JM**, Storek P, Duggan P, et al. An Update on Autologous hematopoietic stem cell transplant in patients with neuromyelitis optica. Fifth Cooperative Meeting of CMSC and ACTRIMS. *International Journal of MS Care* 2013, Vol. 15, No P.3.
15. **Burton JM**, Storek P, Duggan P, et al. An Update on Autologous hematopoietic stem cell transplant in patients with neuromyelitis optica. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2013;19 (Issue 11, Supp): P270.
16. **Burton JM**, Eliasziw M, Trufyn J, et al. An Update on the Role of Vitamin D in Optic Neuritis – An Update. Annual Meeting of the American Academy of Neurology. *Neurology* 2013;80(7): S10.004.
17. **Burton JM**, Eliasziw M, Trufyn J, et al. An Update on the Role of Vitamin D in Optic Neuritis – An Update. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2013;19 (Issue 11 Supp): P1143
18. Costello F, **Burton J**, Trufyn J, et al. Exploring the Temporal Evolution of Structural and Functional Changes after Acute Optic Neuritis. Annual Meeting of the American Academy of Neurology. *Neurology* 2013; 80(7): S47.003
19. Trufyn J, Costello F, Hill M, **Burton J**, et al. The Prevalence of Incidental Findings on Magnetic Resonance Imaging Studies in Multiple Sclerosis Patients. Annual Meeting of the American Academy of Neurology. *Neurology* 2013;80(7): P03.210.
20. Costello F, Pan I, **Burton J**, et al. Capturing axonal and neuronal damage in the anterior visual pathway after optic neuritis. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2013;19 (Issue 11 Supp): P950.

21. Costello F, Hodge W, Pan YI, **Burton J**, et al. Exploring the Temporal Evolution of Structural and Functional Changes After Acute Optic Neuritis". American Academy of Ophthalmology, New Orleans. 2013
22. Trufyn J, Costello D, **Burton J**. Gender and Retinal Nerve Fiber Layer Values in MS Patients. Annual Meeting of the American Academy of Neurology. *Neurology* 2012;78:1 Supplement P01.160.
23. **Burton JM**, Storek P, Duggan P, et al. Autologous hematopoietic stem cell transplant in patients with neuromyelitis optica. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2012;18(S4): P199.
24. Costello F, Hodge W, Pan I, **Burton J**, et al. The Impact of Gender on Recovery from Acute Optic Neuritis: Does Sex Matter? Annual Meeting of the American Academy of Neurology. *Neurology* 2012;78: 1 Supplement: P01.137.
25. **JM Burton** on behalf of the Canadian CCSVI Systematic Review Group (Laupacis A, Lillie E, Dueck A, Strauss S, Perrier L, Burton JM, Aviv R, Thorpe K, Feasby T, Spears J). Systematic Review of the Association between Chronic Cerebral Spinal Venous Insufficiency (CCSVI) and Multiple Sclerosis. Annual Meeting of the American Academy of Neurology. *Neurology* 2012;78: 1 Supplement P05.126.
26. **JM Burton** on behalf of the Canadian CCSVI Systematic Review Group (Laupacis A, Lillie E, Dueck A, Strauss S, Perrier L, Burton JM, Aviv R, Thorpe K, Feasby T, Spears J). Systematic Review of the Association between Chronic Cerebral Spinal Venous Insufficiency (CCSVI) and Multiple Sclerosis. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2012;18(S4).
27. Costello F, Pan YI, **Burton J**, et al. Exploring the temporal evolution of structural and functional changes after acute optic neuritis: a prospective study with spectral-domain optical coherence tomography. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2012;18(S4).
28. **Burton JM**, Tung C, Trufyn J, et al. The Impact of Gender on Recovery from Acute Optic Neuritis. Annual Meeting of the American Academy of Neurology. *Neurology* 2012;78: 1 Supplement: P05.102
29. **Burton JM**, Tung C, Trufyn J, et al. The Role of Vitamin D in Optic Neuritis. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2012;18(S4).

30. Trufyn J, **Burton J**, Costello F. Gender and Retinal Nerve Fiber Layer Values in MS Patients". North American Neuro-Ophthalmology Society (NANOS), 38th Annual Meeting. *J Neuroophthalmol* 2012;32(2): 194.
31. **Burton JM**, Tung C, Trufyn J, Eliasziw M, Costello F on behalf of the Calgary Optic Neuritis Research Group). Evaluating the Impact of Vitamin D Status on Optic Neuritis Characteristics and Recovery. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2011;17 (Issue 10, Supp).
32. **JM Burton** on behalf of the Canadian CCSVI Systematic Review Group (Laupacis A, Lillie E, Dueck A, Strauss S, Perrier L, Burton JM, Aviv R, Thorpe K, Feasby T, Spears J). A Systematic Review of the Association between Chronic Cerebral Spinal Venous Insufficiency (CCSVI) and Multiple Sclerosis. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2011;17 (Issue 10, Supp).
33. Trufyn J, **Burton JM**, Eliasziw M, Jorge S, Metz L, Costello F. Sex and sex hormones in optic nerve integrity. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2011;17 (Issue 10, Supp).
34. Costello F, Hodge W, Pan I, **Burton JM**, Freedman MS, Stys P et al. The impact of gender on retinal nerve fiber layer integrity after acute optic neuritis. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2011;17 (Issue 10 Supp).
35. **Burton JM**, Kimball S, Vieth R, Bar-OR A, Dosch HM, Cheung R, Gagne D, Ursell M, D'Souza C, O'Connor P, "A Phase I/II Dose Escalation Trial of Oral Vitamin D3 with Calcium Supplementation in Patients with Multiple Sclerosis". Presented at the 2010 European Charcot Foundation Symposium, Fiuggi, Italy. *J Neurol Sci* 2011;311(1-2): 1-106.
36. **Burton JM**, Duggan P, Storek J, Bell B, Costello F, Yeung M, Eliasziw M, et al. Autologous hematopoietic stem cell transplant in patients with neuromyelitis optica. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2010; 16 (Supp): P456.
37. **Burton JM**. A Systematic Review of Factors Influencing Vitamin D Status Common to MS Patients. Abstract from the 62nd Annual Academy of Neurology meeting. Annual Meeting of the American Academy of Neurology. *Neurology* 2010;74 (Supp).
38. **Burton JM**, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, Ursell M, D'Souza C, O'Connor P. Immunological Analysis of a Phase I/II Dose-Escalation Trial of Oral Vitamin D3 with Calcium Supplementation in Patients with Multiple Sclerosis. Annual Meeting of the American Academy of Neurology. *Neurology* 2009;72 (Supp).

39. **Burton JM, Kimball S, Vieth R, Bar-Or A, Thibault L, Kilborn S, Dosch HM, Ursell M, D'Souza C, O'Connor P.** A Phase I/II Dose Escalation Trial of Oral Vitamin D3 with Calcium Supplementation in Patients with Multiple Sclerosis. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2008;14: (Issue 1, Supp). S1.P20.
 40. **Burton JM, Kimball S, Vieth R, Bar-OR A, Thibault L, Kilborn S, Dosch HM, Ursell M, D'Souza C, O'Connor P.** A Phase I/II Dose Escalation Trial of Oral Vitamin D3 with Calcium Supplementation in Patients with Multiple Sclerosis. Annual Meeting of the American Academy of Neurology. *Neurology* 2008;70 (Supp).
 41. **Burton JM, Kimball S, Vieth R, Bar-Or A, Thibault L, Kilborn S, Dosch HM, Ursell M, D'Souza C, O'Connor P.** A Phase Ib Safety and Dose Escalation Study of Vitamin D3 with Calcium Supplementation in Patients with Multiple Sclerosis. Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis. *Mult Scler* 2007;13 (Issue 2, Supp).
- vi. Communications
1. Almomen M, Burton JM. Response to "A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy". *Acta Neurol Scand* 2017;135(6): 677-677 (peer-reviewed).
 2. **Burton JM.** Response to "Vitamin D status is negatively correlated with retinal nerve fiber layer thickness in relapsing-remitting MS patients without acute optic neuritis" by Knippenberg et al. *Mult Scler* 2016; 23(1): 129-130. (peer reviewed).